Contineum Q2 net loss $16M, cash $175.5M; PIPE-307 VISTA top line data Q4 2025

Contineum Therapeutics, Inc.

Net loss of $16.0M for Q2 2025 vs $9.0M in Q2 2024; R&D expenses $14.1M (+78% YoY).
Cash and marketable securities $175.5M as of June 30, 2025; cash runway through 2027.
PIPE-307 Phase 2 VISTA (RRMS) top line data expected Q4 2025; PIPE-791 PET data Q3 2025.
Global PIPE-791 Phase 2 IPF trial initiation planned Q4 2025; PrMS and CTX-343 postponed.
Johnson & Johnson Phase 2 Moonlight-1 trial of PIPE-307 in MDD recruiting 124 participants.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.